IcanoMAB, a privately-funded biotech based in Germany, has launched to develop novel precision canonical antibodies for the treatment of cancer, immune-system related diseases and COVID-19.
The company has secured three clinical candidates in IND-enabling stage and funding from MAB Discovery, originally generating the licensed antibodies from a novel antibody discovery platform.
After 10 years of more than 50 successful monoclonal antibody discovery projects with large Pharma and mid- and large-size Biotech companies, MAB Discovery sold its antibody production platform and laboratory to BioNTech (NASDAQ: BNTX) in 2019.
At the end of 2019, a pre-clinical project in the field of Immuno-oncology was licensed to a Top Pharma company.
IcanoMAB will use the proceeds to advance the clinical candidates to allow IND-enabling activities and respective partnering activities with selected third parties.